Stock AUROPHARMA AUROBINDO PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Aurobindo Pharma

Equities

AUROPHARMA

INE406A01037

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:46 2024-04-26 am EDT 		5-day change 1st Jan Change
1,131 INR +2.53% Intraday chart for Aurobindo Pharma +4.07% +4.36%
Apr. 07 Aurobindo Pharma Limited Announces Appointment of T. Vijaya Kumar as President ­ R&D (Specialty Drug Delivery) CI
Apr. 02 Aurobindo Pharma Arms Commission Four New Plants in Andhra Pradesh, India MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 459,504 242,081 516,388 391,729 303,575 662,872 - -
Enterprise Value (EV) 1 507,464 267,882 514,018 373,557 291,348 644,532 627,063 600,010
P/E ratio 19.4 x 8.55 x 9.68 x 14.8 x 15.7 x 21.2 x 17.4 x 15.3 x
Yield 0.32% 0.73% 0.45% 0.67% 0.58% 0.36% 0.44% 0.4%
Capitalization / Revenue 2.35 x 1.05 x 2.08 x 1.67 x 1.22 x 2.31 x 2.11 x 1.95 x
EV / Revenue 2.59 x 1.16 x 2.07 x 1.59 x 1.17 x 2.25 x 1.99 x 1.76 x
EV / EBITDA 13 x 5.55 x 9.64 x 8.52 x 7.86 x 11.3 x 9.54 x 8.19 x
EV / FCF 258 x 8.93 x 27.2 x 12.6 x -90.3 x 41.5 x 22.8 x 16.6 x
FCF Yield 0.39% 11.2% 3.68% 7.93% -1.11% 2.41% 4.39% 6.01%
Price to Book 3.31 x 1.44 x 2.35 x 1.59 x 1.13 x 2.24 x 2.01 x 1.8 x
Nbr of stocks (in thousands) 585,916 585,939 585,939 585,939 585,939 585,939 - -
Reference price 2 784.2 413.2 881.3 668.6 518.1 1,131 1,131 1,131
Announcement Date 5/28/19 6/3/20 5/31/21 5/30/22 5/27/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 195,636 230,985 247,746 234,555 248,554 286,936 314,482 340,754
EBITDA 1 38,917 48,246 53,334 43,868 37,070 56,895 65,731 73,245
EBIT 1 32,237 38,579 42,780 33,324 24,624 41,114 48,778 54,420
Operating Margin 16.48% 16.7% 17.27% 14.21% 9.91% 14.33% 15.51% 15.97%
Earnings before Tax (EBT) 1 30,914 37,430 73,436 33,727 26,125 43,826 51,095 57,445
Net income 1 23,647 28,310 53,348 26,482 19,275 31,435 37,859 42,867
Net margin 12.09% 12.26% 21.53% 11.29% 7.75% 10.96% 12.04% 12.58%
EPS 2 40.36 48.32 91.04 45.19 32.90 53.48 64.88 73.84
Free Cash Flow 1 1,964 29,985 18,910 29,636 -3,226 15,525 27,532 36,048
FCF margin 1% 12.98% 7.63% 12.63% -1.3% 5.41% 8.75% 10.58%
FCF Conversion (EBITDA) 5.05% 62.15% 35.46% 67.56% - 27.29% 41.89% 49.21%
FCF Conversion (Net income) 8.3% 105.92% 35.45% 111.91% - 49.39% 72.72% 84.09%
Dividend per Share 2 2.500 3.000 4.000 4.500 3.000 4.077 4.979 4.501
Announcement Date 5/28/19 6/3/20 5/31/21 5/30/22 5/27/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 63,649 60,015 57,020 59,419 60,022 58,094 62,359 57,394 64,071 64,730 68,505 68,555 74,327 73,148 77,696
EBITDA 1 13,541 12,747 12,094 11,867 10,163 9,744 9,365 7,896 9,538 9,963 11,514 11,963 15,419 15,236 -
EBIT 1 10,776 10,087 9,297 8,925 7,172 5,888 6,570 4,915 6,324 6,508 8,248 8,567 12,165 11,190 11,654
Operating Margin 16.93% 16.81% 16.3% 15.02% 11.95% 10.14% 10.54% 8.56% 9.87% 10.05% 12.04% 12.5% 16.37% 15.3% 15%
Earnings before Tax (EBT) 1 40,054 10,609 10,177 9,676 7,938 5,936 6,790 5,234 6,801 7,301 8,120 8,800 11,846 11,498 -
Net income 1 29,465 8,016 7,700 6,970 6,047 5,765 5,205 4,094 4,913 5,063 5,708 6,061 8,749 8,361 -
Net margin 46.29% 13.36% 13.5% 11.73% 10.08% 9.92% 8.35% 7.13% 7.67% 7.82% 8.33% 8.84% 11.77% 11.43% -
EPS 2 50.29 13.67 13.14 11.89 10.32 9.840 8.880 6.990 8.380 8.640 9.740 10.66 16.32 14.89 14.59
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/10/21 5/31/21 8/12/21 11/8/21 2/9/22 5/30/22 8/11/22 11/12/22 2/9/23 5/27/23 8/12/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 47,960 25,802 - - - - - -
Net Cash position 1 - - 2,370 18,172 12,227 18,341 35,809 62,862
Leverage (Debt/EBITDA) 1.232 x 0.5348 x - - - - - -
Free Cash Flow 1 1,964 29,985 18,910 29,636 -3,226 15,525 27,532 36,048
ROE (net income / shareholders' equity) 19% 20.3% 17% 11.8% 7.5% 11.2% 11.9% 12.1%
ROA (Net income/ Total Assets) 10.2% 11.3% 10.5% 8.11% 5.22% 8.23% 9.67% 10.1%
Assets 1 231,193 251,405 508,929 326,497 369,041 381,827 391,631 422,627
Book Value Per Share 2 237.0 287.0 374.0 419.0 458.0 506.0 562.0 629.0
Cash Flow per Share 2 27.70 74.80 56.80 85.60 40.70 58.50 75.90 87.90
Capex 1 14,257 13,828 14,379 20,529 24,038 20,726 15,733 15,030
Capex / Sales 7.29% 5.99% 5.8% 8.75% 9.67% 7.22% 5% 4.41%
Announcement Date 5/28/19 6/3/20 5/31/21 5/30/22 5/27/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Aurobindo Pharma

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
1,131 INR
Average target price
1,190 INR
Spread / Average Target
+5.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AUROBINDO PHARMA Stock Aurobindo Pharma
+4.36% 7.95B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AUROPHARMA Stock
  4. Financials Aurobindo Pharma